Sanofi SA (ADR) (SNY), Novo Nordisk A/S (ADR) (NVO), Johnson & Johnson (JNJ): Can Investors Bet on These 3 Pharma Companies?

Page 1 of 2

According to the World Health Organization, there are 347 million people around the world who suffer from diabetes.

It is expected that the death rate from diabetes will top 50% in the next ten years, which will make it a leading cause of death worldwide. As such, the overall market for diabetes therapies and diagnostics is estimated to increase from $38 billion in 2010 to $53 billion in 2015. Because of the increasing global trend of more and more people developing diabetes, companies which provide products and services in this domain will benefit.

Here are three companies with big plans to tap the global market with their presence and new product pipeline.

Global leader in diabetes drug

Sanofi SA (ADR) (NYSE:SNY)

Sanofi SA (ADR) (NYSE:SNY) has had nine consecutive quarters of growth in its diabetes drug segment. In the first quarter of 2013, this segment’s sales surged to around $2.41 billion, a growth of 19.6%, year-over-year. Moreover, sale of its diabetes drug, Lantus, increased to around $1.77 billion, growing at around 21.3%, quarter-over-quarter.

Novo Nordisk A/S (ADR) (NYSE:NVO)’s diabetes drug Tresiba was disapproved by the FDA, and will not come to market before 2017 or 2018. As a result of this, Sanofi SA (ADR) (NYSE:SNY)’s Lantus will gain a direct advantage, as it fills the gap in the diabetes segment that Tresiba was expected to compete in.

Moreover, Sanofi SA (ADR) (NYSE:SNY) announced an investment of about $58 million in Waterford, Ireland, to increase Lantus’ production capacity. As a result, the company is expecting higher profits in the third and final quarter of 2013, as well as next year.

Sanofi SA (ADR) (NYSE:SNY) is expecting the European drug authorities to approve its new drug, Lemtrada. This drug is used in the treatment of neurological disorders, and it was obtained through the acquisition of Genzyme in 2011 for around $20.1 billion. The FDA has approved this drug in the U.S, and it has patents until 2017. Approval for Lemtrada in European countries is likely to come in the current fiscal year. It is expected that this drug will boost the revenue of the company. Here’s the drug’s estimated revenue:

Year Estimated revenue from Lemtrada
2014 $243 million
2015 $395 million
2016 $554 million
2017 $657 million
2020 $837 million

Banking on a new drug

Johnson & Johnson (NYSE:JNJ) has a new product pipeline that will strengthen its pharmaceuticals portfolio. The company is expecting to file approvals for 10 new products, and as a part of a multi-branding strategy, will market 25 new products in the next four years.

Recently, J&J’s drug “Invokana” received FDA approval. Invokana is used to treat type 2 diabetes. This drug will have a wholesale price of around $8.77 per tablet and expected dosage is one tablet per day. Invokana was tested on 10,000 patients before getting FDA approval, and the tests showed positive results. There are 26 million people in the U.S. currently suffering from Type 2 diabetes;it’s estimated that Invokana will earn around $111 million in revenue by the end of the current fiscal year, and will rise significantly $667 million by the end of 2016.

The company is focusing on research and development of its immunology and oncology segments. Both these segments account for around 25% of Johnson and Johnson (NYSE:JNJ)’s (J&J) total pharmaceutical sales. The company’s immunology segment showed a 16% increase in revenue, while global sales of oncology drugs grew by 32% in the first quarter of 2013, year-over-year. With this growth, J&J has almost doubled its footprint in the world’s emerging markets. It is further planning to strengthen its product pipeline in countries like China. Due to its expansion in emerging markets, its total global sales from immunology and oncology segment will rise from $7.87 billion in the previous year to $8.82 billion in the current fiscal year.

Page 1 of 2

Dividend Stock Alert - Billionaire Robbins' Top Dividend Idea With 70% Upside Potential

Get Paid 3.5% Per Year While Waiting For The Stock Appreciate 70%

Larry Robbins' Glenview Capital Opportunity Fund returned 101.7% in 2013 and Robbins personally made $750 million. The same fund returned 25.3% in 2014. In this FREE REPORT we will share Robbins' top dividend idea that yields 3.5% and has been increasing its dividends for 39 consecutive years. Robbins thinks the stock has the potential to appreciate 70%.

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Click here to Read Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 74 percentage points in 2.5 years. Our beta is only 1.2 (download a FREE newsletter and see the details inside)

Lists

Best Selling Magazines in the World

Shortest People in History

The Most Celebrated Holidays in the World

Most Expensive Handbag Brands in the World

Top Selling Comic Book Issues of this Century

The Most Powerful Women in Politics

Best Paid DJs

Most Rebellious Female Artists

Best Paid TV Actresses of 2014

Best Paid Actors of 2014

Most Expensive Horses in the World

Tallest People Ever

Most Encouraging Feminist Celebrities

Best Paid Supermodels of 2014

Top 10 Suburbs for Retirement in 2015

10 Wealthiest Cities in America

Top 10 TED Talks for Entrepreneurs

Best TED Talks on Education

25 Most Dangerous Places to Live in America

Top 10 Ski Resorts in the United States – 2014 List

Top 10 Most Remote Places in the World

Most Visited Museums in the United States

Wealthiest Photographers in the World

Most Famous Gay Athletes

The World’s Most Famous Circuses

Best Hair Stylists

Most Popular NASCAR Drivers

The Best Romance Movies of all Time

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!